-
-
Global CDMO Partner for Small Molecules and Peptides
A Strategic Partner for Your Drug Development Journey
We aim to be the reliable and trusted CDMO partner for biotechnology and pharmaceutical companies, delivering excellence, embracing accountability and transparency in every interaction with a tenacious spirit that drives continuous improvement.
We develop and manufacture non-exclusive APIs – both Prime APIs – comprising large volume, mature molecules, and Specialty APIs – comprising lower volume, complex molecules with less competition.
We provide an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Our services include development and manufacturing of peptides from milligrams to multi-kilogram scale by standard sequential chemical peptide syntheses and segment condensation strategies.
About BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO is a global provider of API Contract Development and Manufacturing Organization (CDMO) services. We support biotechnology and pharmaceutical companies in the design, development and manufacturing of complex active pharmaceutical ingredients (APIs).
We develop small molecules and peptides for clinical trials and beyond, with the capacity to scale-up through every stage of the product lifecycle to commercial manufacturing.
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO works to understand our manufacturing process and develops process improvements. The team carefully considers alternatives and implement optimizations.
Sustainability
At BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO, we are actively integrating sustainability and Environmental, Social and Governance (ESG) priorities across our operations. Our sustainability goals have been derived through effective communication with our stakeholders’ end encompass six key themes: environmental stewardship, sustainable supply chain, employee nurturing, upholding human rights and ethics, customer-centricity, and economic value creation.
Frequently Asked Questions
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs is a trusted global CDMO, offering end-to-end support from molecule development to commercialization. With extensive expertise in complex chemistries, our team of scientists ensures seamless project execution for pharmaceutical and biotech companies.
Partnering with a CDMO for drug development and manufacturing offers benefits like access to specialized expertise and infrastructure, cost savings, faster time to market, and scalability, allowing pharma and biotech companies to focus on core competencies.
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs supports the production of complex or niche drug development from milligrams to multi-kilogram scales by standard sequential chemical synthesis and segment condensation strategies. We enable the synthesis of linear and cyclic peptides with dedicated state-of-the-art equipment for custom peptide synthesis while adhering to green chemistry principles.
A CDMO can help optimize drug manufacturing process by leveraging their extensive expertise and resources, accelerating timelines, and ensuring regulatory compliance, from early formulation to commercial scale manufacturing.
Over 4 decades, BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs has been at the forefront of providing end-to-end CDMO services for biotech and pharma clients across 80 countries. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI “SID &GP” Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.
Global regulatory bodies, such as the U.S. FDA, regularly inspect BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs' facilities to ensure high-quality API production. The quality assurance team of our CDMO performs internal audits and follows current Good Manufacturing Practices (cGMP).
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs integrates Green Chemistry by Design (GCbD) into process development, ensuring sustainability without compromising efficiency. By aligning with Quality by Design (QbD) principles, GCbD enhances API manufacturing through optimized synthetic routes, reduced environmental impact, and improved scalability. A robust sustainability framework guides efforts toward a low-carbon economy, responsible business practices, and community empowerment. With a seamless transition from process research to scalable green manufacturing, BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs remains committed to developing cost-effective and environmentally responsible solutions.
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs ensures transparent and reliable supply chain management through robust planning, risk mitigation, and proactive communication. Our dedicated supply chain team oversees supplier onboarding, risk de-risking, and alternate scouting to secure high-quality materials while maintaining fairness, localization, and sustainability in all dealings.
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs takes intellectual property protection seriously, implementing a comprehensive IP management strategy that includes regular audits, due diligence, and infringement monitoring. Our E-Patent management system provides real-time IP data, enabling both our team and clients to make informed, risk-aware decisions.
BRISTO PHARMACEUTICAL COMPANY CANADA TORONTO Labs primarily collaborates with pharmaceutical and biotech companies as a CDMO partner, supporting them across the drug development lifecycle—from molecule development to commercialization. The company engages in strategic partnerships that emphasize process innovation, regulatory compliance, and supply chain efficiency.
Our Capabilities
Our Facilities
